Ameriprise Financial Inc Trevena Inc Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.16 - $100.0 $992 - $620,000	-6,200 Reduced 35.03%	11,500 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.2 - $0.5 $400 - $1,000	-2,000 Reduced 10.15%	17,700 $7,000
Q1 2022 May 16, 2022	SELL	$0.41 - $0.63 $205 - $315	-500 Reduced 2.48%	19,700 $11,000
Q4 2021 Feb 14, 2022	SELL	$0.57 - $1.29 $22,495 - $50,909	-39,465 Reduced 66.14%	20,200 $12,000
Q3 2021 Nov 15, 2021	SELL	$1.11 - $1.7 $3,257 - $4,989	-2,935 Reduced 4.69%	59,665 $73,000
Q2 2021 Aug 16, 2021	BUY	$1.46 - $2.25 $292 - $450	200 Added 0.32%	62,600 $106,000
Q1 2021 May 17, 2021	BUY	$1.77 - $2.93 $12,567 - $20,803	7,100 Added 12.84%	62,400 $112,000
Q4 2020 Feb 12, 2021	BUY	$2.13 - $3.26 $65,604 - $100,408	30,800 Added 125.71%	55,300 $118,000
Q3 2020 Nov 16, 2020	BUY	$1.53 - $3.13 $37,485 - $76,685	24,500 New	24,500 $73,000
Q1 2018 May 15, 2018	SELL	$1.51 - $2.06 $36,344 - $49,582	-24,069 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$2.22 - $2.79 $53,433 - $67,152	24,069	24,069 $61,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.